XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)

6 Months Ended

Jun. 30, 2023

Concentration Risk And Geographic Information [Abstract]

Schedule of Net Product Revenues by Product

The following table disaggregates total Net Product Revenues by product.

			Three Months Ended June 30,												Six Months Ended June 30,
			2023						2022						2023						2022
Enzyme product revenues:
VIMIZIM			$	177,392					$	173,206					$	366,584					$	356,265
NAGLAZYME			90,103						115,783						213,124						243,814
PALYNZIQ			74,868						61,643						137,220						116,528
ALDURAZYME			40,318						37,327						74,721						61,709
BRINEURA			38,058						37,725						77,202						73,898
Total enzyme product revenues			420,739						425,684						868,851						852,214
VOXZOGO			113,337						34,374						201,173						54,032
KUVAN			50,622						57,602						101,100						116,939
Total net product revenues			584,698						517,660						1,171,124						1,023,185
Royalty and other revenues			10,577						16,138						20,566						29,972
Total revenues			$	595,275					$	533,798					$	1,191,690					$	1,053,157

Schedule of Total Net Product Revenues Based on Patient Location

The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.

			Three Months Ended June 30,												Six Months Ended June 30,
			2023						2022						2023						2022
United States			$	191,655					$	169,838					$	358,439					$	320,653
Europe			183,434						161,231						344,126						318,062
Latin America			75,444						89,911						143,192						152,455
Middle East			25,630						21,414						117,272						87,021
Rest of world			68,217						37,939						133,374						83,285
Total net product revenues marketed by the Company			$	544,380					$	480,333					$	1,096,403					$	961,476
ALDURAZYME net product revenues marketed by Sanofi			40,318						37,327						74,721						61,709
Total net product revenues			$	584,698					$	517,660					$	1,171,124					$	1,023,185

Schedule of Net Product Revenue Concentrations Attributed to Largest Customers

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 

			Three Months Ended June 30,												Six Months Ended June 30,
			2023						2022						2023						2022
Customer A			15		%				16		%				15		%				16		%
Customer B			12		%				12		%				11		%				12		%
Customer C			10		%				9		%				9		%				8		%
Total			37		%				37		%				35		%				36		%

X

- Definition

Concentration risk and geographic information.

+ References

No definition available.

+ Details

Name:	bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix:	bmrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration